


Stabilis



Palonosetron hydrochloride



Noms commerciaux

| | |
|--------------|---|
| Aloxi | Allemagne, Autriche, Belgique, Canada, Danemark, Espagne, Etats Unis d'Amérique, Finlande, Grande Bretagne, Grèce, Hongrie, Irlande, Islande, Italie, Japon, Luxembourg, Malaisie, Norvège, Pays bas, Pologne, Portugal, Roumanie, Suède, Suisse, |
| Chepatron | Inde |
| Cinvex | Turquie |
| Factoket | Mexique |
| Lotisa | Turquie |
| Onicit | Chili, Colombie, Equateur, Italie, Pérou |
| Palohalt | Chili, Pérou |
| Paloject | Turquie |
| Palonosetron | Allemagne, Belgique, Chili, Equateur, Espagne, France, Grande Bretagne, Suisse |
| Palostar | Inde |
| Palzen | Inde |
| Vinaltro | Mexique |
| Viqet | Mexique |
| Vonaxi | Turquie |



Stabilité des solutions

| Container | Concentration | Température | Exposition à la lumière | Durée | Stabilité | Autres | Code |
|-----------|---------------|-------------|-------------------------|-------|-----------|--------|------|
| RL | 25 µg/ml | 25°C | ? | 4 | ✓ | | 2281 |
| PVC | 5 & 30 µg/ml | 23°C | ☀ | 48 | ✓ | | 1936 |
| PVC | 5 & 30 µg/ml | 4°C | ☀ (interdit) | 14 | ◐ | | 1936 |



Stabilité en mélange

| | | 25 µg/ml | 25°C | | Ampicillin sodium - sulbactam sodium : 20/10 mg/ml | 4 | 2214 |
|--|--|------------|-----------|--|--|---|------|
| | | 25 µg/ml | ? | | Cisplatine : 0,25 mg/ml | 4 | 1950 |
| | | 25 µg/ml | 20°C-25°C | | Lorazepam : 0,25 mg/ml | 4 | 1975 |
| | | 25 µg/ml | 20°C-25°C | | Midazolam hydrochloride : 1 mg/ml | 4 | 1975 |
| | | 25 µg/ml | 20°C-25°C | | Topotecan : 0,05 mg/ml | 4 | 1976 |
| | | 25 µg/ml | 20°C-25°C | | Irinotecan : 0,5 mg/ml | 4 | 1976 |
| | | 25 µg/ml | 23°C | | Doxorubicin hydrochloride : 0,1 mg/ml | 4 | 1955 |
| | | 26 µg/ml | 23°C | | Epirubicin hydrochloride : 0,26 mg/ml | 4 | 1955 |
| | | 26 µg/ml | 25°C | | Fluorouracil : 0,08 mg/ml | 4 | 2009 |
| | | 26 µg/ml | 25°C | | Gemcitabine hydrochloride : 0.105 mg/ml | 4 | 2009 |
| | | 25 µg/ml | 25°C | | Dacarbazine : 0,05 mg/ml | 4 | 2107 |
| | | 50 µg/ml | 25°C | | Cyclophosphamide : 10 mg/ml | 4 | 2016 |
| | | 50 µg/ml | 25°C | | Ifosfamide : 20 mg/ml | 4 | 2016 |
| | | 25 µg/ml | 25°C | | Atropine sulfate : 0,19 mg/ml | 4 | 2279 |
| | | 25 µg/ml | 25°C | | Heparin sodium : 50 UI/ml | 4 | 2279 |
| | | 25 µg/ml | 25°C | | Lidocaine hydrochloride : 5,3 mg/ml | 4 | 2279 |
| | | 25 µg/ml | 25°C | | Potassium chloride : 50 mEq/l | 4 | 2279 |
| | | 25 µg/ml | 25°C | | Famotidine : 1 mg/ml | 4 | 2279 |
| | | 26 µg/ml | 25°C | | Suxamethonium chloride : 1.05 mg/ml | 4 | 2227 |
| | | 25 µg/ml | 25°C | | Rocuronium bromide : 0.5 mg/ml | 4 | 2227 |
| | | 25.4 µg/ml | 25°C | | Cisatracurium besylate : 0.26 mg/ml | 4 | 2227 |
| | | 26,6 µg/ml | 25°C | | Paclitaxel : 0,62 mg/ml | 4 | 1940 |
| | | 26,6 µg/ml | 25°C | | Docetaxel : 0,41 mg/ml | 4 | 1940 |
| | | 25 µg/ml | 25°C | | Promethazine hydrochloride : 1 mg/ml | 4 | 2179 |
| | | 25.6 µg/ml | 25°C | | Vecuronium bromide : 0.5 mg/ml | 4 | 2227 |
| | | 26.7 µg/ml | 25°C | | Gentamicin sulfate : 5.26 mg/ml | 4 | 2228 |
| | | 25 µg/ml | 25°C | | Metronidazole : 2.6 mg/ml | 4 | 2228 |
| | | 27 µg/ml | 25°C | | Vancomycin hydrochloride : 4.9 mg/ml | 4 | 2228 |
| | | 25 µg/ml | 25°C | | Cefazolin sodium : 10 mg/ml | 4 | 2214 |
| | | 25 µg/ml | ? | | Carboplatin : 2,5 mg/ml | 4 | 1950 |










































| | | | | | | | | |
|--|--|------------|---------|--|--|----|--|------|
| | | 25 µg/ml | ? | | Oxaliplatin : 0,25 mg/ml | 4 | | 1950 |
| | | 2,28 µg/ml | 2-8°C | | Rolapitant : 1,65 mg/ml | 7 | | 3928 |
| | | 2,1 µg/ml | 2-8°C | | Rolapitant : 1,6 mg/ml Dexamethasone sodium phosphate : 0,178 mg/ml | 48 | | 4062 |
| | | 2,1 µg/ml | 2-8°C | | Rolapitant : 1,6 mg/ml Dexamethasone sodium phosphate : 0,093 mg/ml | 48 | | 4062 |
| | | 2,28 µg/ml | 20-25°C | | Rolapitant : 1,65 mg/ml | 2 | | 3928 |
| | | 2,1 µg/ml | 20-25°C | | Rolapitant : 1,6 mg/ml Dexamethasone sodium phosphate : 0,093 mg/ml | 24 | | 4062 |
| | | 2,1 µg/ml | 20-25°C | | Rolapitant : 1,6 mg/ml Dexamethasone sodium phosphate : 0,178 mg/ml | 24 | | 4062 |
| | | 25 µg/ml | 25°C | | Fentanyl citrate : 25 µg/ml | 4 | | 2196 |
| | | 25 µg/ml | 25°C | | Hydromorphone hydrochloride : 0,25 mg/ml | 4 | | 2196 |
| | | 25 µg/ml | 25°C | | Morphine sulfate : 7,7 mg/ml | 4 | | 2196 |
| | | 25 µg/ml | 25°C | | Sufentanil citrate : 7 mg/ml | 4 | | 2196 |
| | | 25 µg/ml | 25°C | | Sufentanil citrate : 0.0062 mg/ml | 4 | | 2196 |
| | | 25 µg/ml | 25°C | | Metoclopramide hydrochloride : 25 mg/ml | 4 | | 2179 |
| | | 25 µg/ml | 25°C | | Neostigmine methylsulfate : 0,25 mg/ml | 4 | | 2286 |
| | | 25 µg/ml | 25°C | | Glycopyrronium bromide : 0,1 mg/ml | 4 | | 2286 |
| | | 25 µg/ml | 25°C | | Pethidine hydrochloride : 5,5 mg/ml | 4 | | 2196 |
| | | 5 µg/ml | 25°C | | Dexamethasone sodium phosphate : 0,2 & 0,4 mg/ml | 48 | | 1932 |
| | | 5 µg/ml | 4°C | | Dexamethasone sodium phosphate : 0,2 & 0,4 mg/ml | 14 | | 1932 |
| | | 25 µg/ml | 25°C | | Dexamethasone sodium phosphate : 0,33 mg/ml | 48 | | 1932 |
| | | 25 µg/ml | 4°C | | Dexamethasone sodium phosphate : 0,33 mg/ml | 14 | | 1932 |
| | | 25 µg/ml | 25°C | | Propofol : 5 mg/ml | 4 | | 2312 |
| | | 2.5 µg/ml | 23-27°C | | Dexamethasone sodium phosphate : 0,2 mg/ml | 48 | | 3981 |
| | | 2.5 µg/ml | 23-27°C | | Dexamethasone sodium phosphate : 0,1 mg/ml | 48 | | 3981 |
| | | 2,28 µg/ml | 2-8°C | | Rolapitant : 1,65 mg/ml | 7 | | 3928 |
| | | 2,28 µg/ml | 20-25°C | | Rolapitant : 1,65 mg/ml | 2 | | 3928 |



Compatibilités

| | | | | |
|--|---|--|--|------|
| | | | | |
| | Palonosetron hydrochloride : 50 µg/ml Ampicillin sodium - sulbactam sodium : 20/10 mg/ml | | | 2214 |
| | Palonosetron hydrochloride : 50 µg/ml Atropine sulfate : 0.4 mg/ml | | | 2279 |

| | | | |
|--|--|-----------|------|
| | Palonosetron hydrochloride : 50 µg/ml Carboplatin : 5 mg/ml | | 1950 |
| | Palonosetron hydrochloride : 50 µg/ml Cefazolin sodium : 20 mg/ml | | 2214 |
| | Palonosetron hydrochloride : 50 µg/ml Cisatracurium besylate : 0,5 mg/ml | | 2227 |
| | Palonosetron hydrochloride : 50 µg/ml Cisplatin : 0,5 mg/ml | | 1950 |
| | Palonosetron hydrochloride : 50 µg/ml Cyclophosphamide : 10 mg/ml | | 2016 |
| | Palonosetron hydrochloride : 50 µg/ml Dacarbazine : 4 mg/ml | | 2107 |
| | Palonosetron hydrochloride : 2.5 µg/ml Dexamethasone sodium phosphate : 0.1 & 0.2 mg/ml | | 3981 |
| | Palonosetron hydrochloride : 5 & 25 µg/ml Dexamethasone sodium phosphate : 0,2 >> 0,4 mg/ml | | 1932 |
| | Palonosetron hydrochloride : 50 µg/ml Docetaxel : 0,8 mg/ml | | 1940 |
| | Palonosetron hydrochloride : 50 µg/ml Doxorubicin hydrochloride : 1 mg/ml | | 1955 |
| | Palonosetron hydrochloride : 50 µg/ml Epirubicin hydrochloride : 0,5 mg/ml | | 1955 |
| | Palonosetron hydrochloride : 50 µg/ml Famotidine : 2 mg/ml | | 2279 |
| | Palonosetron hydrochloride : 50 µg/ml Fentanyl citrate : 50 µg/ml | | 2196 |
| | Palonosetron hydrochloride : 50 µg/ml Fluorouracil : 16 mg/ml | | 2009 |
| | Palonosetron hydrochloride : 2 µg/ml Fosaprepitant dimeglumine : 1 mg/ml | | 3459 |
| | Palonosetron hydrochloride : 50 µg/ml Gemcitabine hydrochloride : 10 mg/ml | | 2009 |
| | Palonosetron hydrochloride : 50 µg/ml Gentamicin sulfate : 5 mg/ml | | 2228 |
| | Palonosetron hydrochloride : 50 µg/ml Glycopyrronium bromide : 0,2 mg/ml | | 2286 |
| | Palonosetron hydrochloride : 50 µg/ml Heparin sodium : 100 UI/ml | | 2279 |
| | Palonosetron hydrochloride : 50 µg/ml Hetastarch : 60 mg/ml | RL | 2281 |
| | Palonosetron hydrochloride : 50 µg/ml Hydromorphone hydrochloride : 0.5 mg/ml | | 2196 |
| | Palonosetron hydrochloride : 50 µg/ml Ifosfamide : 20 mg/ml | | 2016 |
| | Palonosetron hydrochloride : 50 µg/ml Irinotecan : 1 mg/ml | | 1976 |
| | Palonosetron hydrochloride : 50 µg/ml Lidocaine hydrochloride : 10 mg/ml | | 2279 |
| | Palonosetron hydrochloride : 50 µg/ml Lorazepam : 0,5 mg/ml | | 1975 |
| | Palonosetron hydrochloride : 50 µg/ml Mannitol : 150 mg/ml | | 2281 |

| | | | | |
|--|---|--|--|------|
|  |  | Palonosetron hydrochloride : 50 µg/ml Methylprednisolone sodium succinate : 5 mg/ml |  | 2107 |
| |  | Palonosetron hydrochloride : 50 µg/ml Metoclopramide hydrochloride : 50 mg/ml |  | 2179 |
| |  | Palonosetron hydrochloride : 50 µg/ml Metronidazole : 5 mg/ml |  | 2228 |
| |  | Palonosetron hydrochloride : 50 µg/ml Midazolam hydrochloride : 2 mg/ml |  | 1975 |
| |  | Palonosetron hydrochloride : 50 µg/ml Morphine sulfate : 15 mg/ml |  | 2196 |
| |  | Palonosetron hydrochloride : 50 µg/ml Neostigmine methylsulfate : 0,5 mg/ml |  | 2286 |
| |  | Palonosetron hydrochloride : 50 µg/ml Oxaliplatin : 0,5 mg/ml |  | 1950 |
| |  | Palonosetron hydrochloride : 50 µg/ml Paclitaxel : 1,2 mg/ml |  | 1940 |
| |  | Palonosetron hydrochloride Paclitaxel albumin : 5 mg/ml |  | 4310 |
| |  | Palonosetron hydrochloride : 50 µg/ml Pethidine hydrochloride : 10 mg/ml |  | 2196 |
| |  | Palonosetron hydrochloride : 50 µg/ml Potassium chloride : 100 mEq/l |  | 2279 |
| |  | Palonosetron hydrochloride : 50 µg/ml Promethazine hydrochloride : 2 mg/ml |  | 2179 |
| |  | Palonosetron hydrochloride : 50 µg/ml Propofol : 10 mg/ml |  | 2312 |
| |  | Palonosetron hydrochloride : 50 µg/ml Rocuronium bromide : 1 mg/ml |  | 2227 |
| |  | Palonosetron hydrochloride : 2.5 µg/ml Rolapitant : 1.65 mg/ml |  | 3928 |
| |  | Palonosetron hydrochloride : 50 µg/ml Sufentanil citrate : 0.0125 mg/ml |  | 2196 |
| |  | Palonosetron hydrochloride : 50 µg/ml Suxamethonium chloride : 2 mg/ml |  | 2227 |
| |  | Palonosetron hydrochloride : 50 µg/ml Topotecan : 0,1 mg/ml |  | 1976 |
| |  | Palonosetron hydrochloride : 50 µg/ml Vancomycin hydrochloride : 5 mg/ml |  | 2228 |
| |  | Palonosetron hydrochloride : 50 µg/ml Vecuronium bromide : 1 mg/ml |  | 2227 |



Voie d'administration





Bibliographie

| | Type | Source |
|------|-------|--|
| 1932 | Revue | Trissel LA, Zhang Y. Compatibility and stability of Aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate. Int J Pharm Compound 2004 ; 8,5: 398-403. |
| 1936 | Revue | Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCl in 4 infusion solutions. Ann Pharmacotherapy 2004 ; 38: 1608-1611. |
| 1940 | Revue | Xu QA, Trissel LA. Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 1596-1598. |
| 1950 | Revue | Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195. |
| 1955 | Revue | Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann Pharmacotherapy 2005 ; 39: 280-283. |
| 1975 | Revue | Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 235-237. |
| 1976 | Revue | Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 238-241. |
| 2009 | Revue | Trissel LA, Zhang Y. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 2005, 9, 4: 320-322. |
| 2016 | Revue | Xu QA, Trissel LA. Compatibility of palonosetron with cyclophosphamide and with ifosfamide during Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 1998-2000. |
| 2107 | Revue | Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration. Int J Pharm Compound 2006 ; 10: 234-236. |
| 2179 | Revue | Trusley C, Ben M, Kupiec TC, Trissel LA. Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration. Int J Pharm Compound 2007 ; 11, 1: 82-85. |
| 2196 | Revue | Trissel LA, Trusley C, Ben M, Kupiec TC. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration. Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213. |
| 2214 | Revue | Ben M, Trusley C, Kupiec T.C, Trissel L.A. Palonosetron hydrochloride compatibility and stability with three beta-lactam antibiotics during simulated Y-site administration. Int J Pharm Compound 2007 ; 11, 6: 520-524. |

| | | |
|------|-------|--|
| 2227 | Revue | Trusley C, Ben M, Kupiec TC, Trissel LA. Compatibility and stability of palonosetron hydrochloride with four neuromuscular blocking agents during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 2: 156-160. |
| 2228 | Revue | Kupiec T, Ben M, Trusley C, Trissel LA. Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration. Int J Pharm Compound 2008 ; 12,2: 170-173. |
| 2279 | Revue | Kupiec T, Trusley C, Ben M, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759. |
| 2281 | Revue | Ben M, Kupiec T, Trusley C, Trissel LA. Compatibility and stability of palonosetron hydrochloride with lactated Ringer's, Hetastarch in lactated electrolyte, an mannitol injections during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 5: 460-462. |
| 2286 | Revue | Ben M, Trusley C, Kupiec TC, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 4: 368-371. |
| 2312 | Revue | Trissel L.A, Trusley C, Kupiec T.C, Ben M. Compatibility and stability of palonosetron hydrochloride and propofol during simulated Y-site administration. Int J Pharm Compound 2009 ; 13, 1: 78-80. |
| 3459 | Revue | Sun S, Schaller J, Placek J, Duersch B. Compatibility of intravenous fosaprepitant with intravenous 5-HT ₃ antagonists and corticosteroids. Cancer Chemother Pharmacol 2013 ; 72: 509-513. |
| 3928 | Revue | Wu G, Yeung S, Chen F. Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride. Int J Pharm Compound 2017 ; 21, 1: 76-82. |
| 3981 | Revue | He G, Zeng F, Lei K, Xia S, Deng L, Zhang C, Liu D. Compatibility of dexamethasone sodium phosphate with 5-HT ₃ receptor antagonists in infusion solutions: a comprehensive study EJHP 2017 ;24:162?166 |
| 4062 | Revue | Wu George, Powers Dan, Yeung S, Chen F, Neelon K. Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous palonosetron hydrochloride injection and dexamethasone sodium phosphate injection. Int J Pharm Compound 2018 ;22,1:76-85 |
| 4310 | Revue | Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M. Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs. Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16. |



Dictionnaire

| | |
|---|---|
|  Antiémétique |  Injectable |
|  Noms commerciaux |  Stabilité des solutions |
|  Contenant |  Molécule |
|  Concentration |  Température |
|  Conservation |  Durée de stabilité |
|  Biosimilaire |  Données conflictuelles |
|  Bibliographie |  Verre |
| RL Ringer lactate |  Non précisée |
|  Heure |  Polyvinyl chlorure |
|  NaCl 0,9% ou glucose 5% |  Lumière |
|  A l'abri de la lumière |  Jour |
|  Stabilité en mélange |  Solvant |
|  Molécule |  Chlorure de sodium 0,9% |
|  Glucose 5% |  Aucun |
|  Polypropylène |  Polyoléfine |
|  Cristal Zenith® |  Compatibilités |
|  Compatible |  Instabilité chimique |
|  Incompatible |  Précipitation en 4 heures |
|  Voie d'administration |  Intraveineuse |
|  Bibliographie |  Dictionnaire |